leadf
logo-loader
viewActinogen Medical Ltd

Actinogen moves to next stage of Alzheimer's treatment trials

Biotech Actinogen has signed 174 patients for its trial of the drug Xanamem, which may offer a novel new treatment of Alzheimer's disease.

Managing Director Dr Bill Ketelbey says the drug, which treats increased cortisol levels that may decrease cognitive ability, could be "an enormously valuable asset" even though it only treats, rather then cures Alzheimer's.

Quick facts: Actinogen Medical Ltd

Price: 0.029 AUD

ASX:ACW
Market: ASX
Market Cap: $32.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FastForward Innovations on FCA's green light to medical cannabis listings...

FastForward Innovations Limited's (LON:FFWD) Ed McDermott talks to Proactive London about the FCA's new approach to medical cannabis and as the 'only AIM listed company that has had direct investment in cannabis' this is very significant for the firm. As Mcderrmott explains the UK’s financial...

40 minutes ago

2 min read